He is chief medical officer for M2Gen, a Moffitt Cancer Center biotechnology company. He is also a professor at the University of South Florida’s Departments of Oncologic Sciences, Internal Medicine and Molecular Medicine. Dr. Sullivan’s research interests include the mechanism of drug resistance to common anti-tumor agents for patient with hematologic malignancies, small cell lung cancer, malignant melanoma and rectal carcinoma.
Dr. Sullivan received his bachelor’s degree and medical degree, followed by a master’s degree in biochemistry from the University of Louisville, KY. He completed a fellowship in hematology/oncology from the University of Florida.